Loading viewer...
investor_presentation
Format: PDF investor_presentation
® ® CORPORATE PRESENTATION NO VEMBER 2 0 2 0
CORPORATE PRESENTATION
2NOTE REGARDING FORWARD -LOOKING STATEMENTS
AND NON -GAAP FINANCIAL MEASURES
This presentation includes forward -looking statements thatinvolve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.(“Regeneron” orthe“Company”), andactual events orresults may differ materially from
these forward -looking statements .Words such as“anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations ofsuch words, andsimilar expressions areintended toidentify such forward -looking statements, although notallforward -looking statements
contain these identifying words .These statements concern, and these risks and uncertainties include, among others, theimpact ofSARS -CoV-2(the virus that hascaused theCOVID -19pandemic) onRegeneron's business and itsemployees, collaborators, and
suppliers and other third parties onwhich Regeneron relies, Regeneron's and itscollaborators’ ability tocontinue toconduct research and clinical programs, Regeneron's ability tomanage itssupply chain, netproduct sales ofproducts marketed orotherwise
commercialized byRegeneron and/or itscollaborators (collectively, "Regeneron’s Products"), andtheglobal economy ;thenature, timing, andpossible success andtherapeutic applications ofRegeneron’s Products andRegeneron’s product candidates andresearch and
clinical programs now underway orplanned, including without limitation EYLEA®(aflibercept) Injection, Dupixent®(dupilumab), Libtayo®(cemiplimab), Praluent®(alirocumab), Kevzara®(sarilumab), InmazebTM(atoltivimab ,maftivimab ,andodesivimab -ebgn ),REGN -COV 2,
fasinumab, evinacumab, garetosmab, pozelimab ,Regeneron’s oncology programs (including itscostimulatory bispecific portfolio), Regeneron’s earlier -stage programs, andtheuseofhuman genetics inRegeneron’s research programs ;safety issues resulting from the
administration ofRegeneron’s Products andproduct candidates inpatients, including serious complications orside effects inconnection with theuseofRegeneron’s Products andproduct candidates inclinical trials ;thelikelihood, timing, andscope ofpossible regulatory
approval andcommercial launch ofRegeneron’s product candidates andnew indications forRegeneron’s Products including without limitation EYLEA, Dupixent, Libtayo, Praluent, Kevzara, Inmazeb ,REGN -COV 2,fasinumab, evinacumab, garetosmab, pozelimab ,and
Regeneron’s oncology programs (including itscostimulatory bispecific portfolio) ;thelikelihood andtiming ofachieving anyoftheanticipated milestones described inthispresentation ;theextent towhich theresults from theresearch anddevelopment programs conducted
byRegeneron and/or itscollaborators may bereplicated inother studies and/or lead toadvancement ofproduct candidates toclinical trials, therapeutic applications, orregulatory approval ;ongoing regulatory obligations andoversight impacting Regeneron’s Products
investor_presentation
d’Amico International Shipping
Preview truncated — download the full document for the complete content.
investor_presentation
23 Pages
Cascades
investor_presentation
Evolus
investor_presentation
OneSpan